For the roughly one-quarter of eosinophilic esophagitis patients who also experience joint hypermobility, the disease may be fundamentally different — not just a variation in severity, but a biologically distinct subtype driven by mast cell activity and autonomic nervous system dysregulation. That distinction carries real implications for diagnosis, symptom management, and quality of life in pediatric patients who are frequently misunderstood or underdiagnosed.
In a prospective cohort of 80 pediatric EoE patients at Lurie Children's Hospital, researchers systematically mapped the overlap between dysautonomia and joint hypermobility using validated scoring tools including the COMPASS-31 autonomic symptom scale, the Pediatric EoE Symptom Score, and the Beighton hypermobility scoring system. Autonomic symptom burden was significantly elevated in EoE patients relative to published controls, and was further amplified during active disease compared to remission. Approximately 26% of the cohort met criteria for joint hypermobility, and this group demonstrated higher autonomic symptom scores alongside correlations with gastric and duodenal mast cell infiltration — a mechanistic thread linking connective tissue vulnerability to immune dysregulation at the gut level.
This work sits at the intersection of several converging research streams. The hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder communities have long recognized a clustering of mast cell activation, dysautonomia, and gastrointestinal dysmotility — sometimes called the "mast cell-hypermobility-dysautonomia triad" — but formal characterization within specific GI conditions like EoE has lagged. This study begins to fill that gap in a pediatric context. Key limitations include the single-center design, reliance on survey-based hypermobility assessment, and a sample size that limits subgroup power. The mast cell data is compelling but correlational; whether mast cell density causally drives autonomic symptoms or both arise from a shared connective tissue pathology remains unresolved. Still, for clinicians managing treatment-refractory EoE in children with fatigue, dizziness, or widespread pain, this research offers a framework for recognizing a clinically meaningful subgroup that may require a broader, multisystem treatment approach.